Full Length Research Paper
References
|
Avong YK, Isaakidis P, Hinderaker SG, Van den Bergh R, Ali E, Obembe BO, Dakum PS (2015). Doing no harm? Adverse events in a nation-wide cohort of patients with multidrug-resistant tuberculosis in Nigeria. PLoS One 10(3):e0120161. Crossref |
||||
|
Black RE, Lau WK, Weinstein RJ, Young LS, Hewitt WL (1976). Ototoxicity of amikacin. Antimicrobial Agents Chemotherapy 9(6):956-961. Crossref |
||||
| de Jager P, van Altena R (2002). Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. International Journal of Tuberculosis and Lung Dieaase 6(7):622-627. | ||||
|
Duggal P, Sarkar M (2007). Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up. BMC Ear Nose Throat Disorder 7:5. Crossref |
||||
|
Fausti SA, Henry JA, Schaffer HI, Olson DJ, Frey RH, McDonald WJ (1992). High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity. Journal of Infectious Disease 165(6):1026-1032. Crossref |
||||
|
Ganesan P, Schmiedge J, Manchaiah V, Swapna S, Dhandayutham S, Kothandaraman PP (2018). Ototoxicity: A Challenge in Diagnosis and Treatment. Journal of Audiology and Otology 22(2):59-68. Crossref |
||||
|
Harris T, Bardien S, Schaaf HS, Petersen L, De Jong G, Fagan JJ (2012). Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients. South African Medical Journal 102(6). Crossref |
||||
|
Hawkins JE (1976). Drug ototoxicity. Handbook of sensory physiology 5:707-748. Crossref |
||||
|
Hong H, Budhathoki C, Farley JE (2018). Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection. International Journal of Tuberculosis Lung Disease 22(6):667-674. Crossref |
||||
|
Ibekwe M, Nwosu C (2016). Pure tone audiometric findings in patients on second-line treatment for multidrug-resistant tuberculosis. Port Harcourt Medical Journal 10(3):97-101. Crossref |
||||
|
Kurbatova EV, Cegielski JP, Lienhardt C, Akksilp R, Bayona J, Becerra MC, Zignol M (2015). Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respiratory Medical 3(3):201-209. Crossref |
||||
|
Modongo C, Sobota RS, Kesenogile B, Ncube R, Sirugo G, Williams SM, Zetola NM (2014). Successful MDR-TB treatment regimens including Amikacin are associated with high rates of hearing loss. BMC Infectious Diseases 14(1):542. Crossref |
||||
|
Schnippel K, Berhanu RH, Black A, Firnhaber C, Maitisa N, Evans D, Sinanovic E (2016). Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study. BMC Infectious Diseases 16(1):593. Crossref |
||||
| Sharma V, Bhagat S, Verma B, Singh R, Singh S (2016). Audiological Evaluation of Patients Taking Kanamycin for Multidrug Resistant Tuberculosis. Iranian Journal of Otorhinolaryngology 28(86):203-208. | ||||
|
Sogebi OA, Adefuye BO, Adebola SO, Oladeji SM, Adedeji TO (2017). Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy. Auris Nasus Larynx 44(4):404-410. Crossref |
||||
|
Sturdy A, Goodman A, José RJ, Loyse A, O'Donoghue M, Kon OM, Cooke GS (2011). Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. Journal of Antimicrobial Chemotherapy 66(8):1815-1820. Crossref |
||||
| Torun T, Gungor G, Ozmen I, Bolukbasi Y, Maden E, Bicakci B, Tahaoglu K(2005). Side effects associated with the treatment of multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease 9(12):1373-1377. | ||||
|
Vakulenko SB and Mobashery S (2003). Versatility of Aminoglycosides and Prospects for Their Future. Clinical Microbiology Reviews, 16(3):430-450. Crossref |
||||
|
World Health Organization (WHO) (2016). WHO drug treatment guidelines for drug resistant tuberculosis. |
||||
|
Yang TW, Park HO, Jang HN, Yang JH, Kim SH. Moon SH, Kang DH (2017). Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: A retrospective study. Medicine (Baltimore) 96(28):e7482. Crossref |
||||
Copyright © 2025 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
